The Predictive Value of Serum Total IgE for Antihistamine Treatment Outcomes in Chinese Patients with Chronic Spontaneous Urticaria
DOI:
https://doi.org/10.2340/actadv.v105.43568Keywords:
chronic urticaria, IgE, antihistamine, antihistamine refractoriness, predictive factorsAbstract
Chronic spontaneous urticaria is a common skin disorder with variable treatment responses. Second-generation H1-antihistamines are the first-line treatment for chronic spontaneous urticaria, yet many patients fail to respond to licensed doses. Predictors of treatment response to second-generation H1-antihistamines could help optimize disease management and minimize unnecessary healthcare costs. In this retrospective cohort study of 99 Chinese chronic spontaneous urticaria patients, higher log-transformed serum total IgE levels were significantly associated with poor response to standard-dose antihistamines (aOR = 2.09, 95% CI: 1.29–3.38, p = 0.003). However, this association was not observed in the subgroup of patients who required dose escalation, suggesting a more complex relationship in later treatment stages. Machine learning analysis further supported total IgE as one of the top predictors of poor response to standard-dose second-generation H1-antihistamines. While serum total IgE may not serve as a diagnostic tool, it appears to be a helpful risk indicator for anticipating refractoriness to standard-dosed antihistamines in chronic spontaneous urticaria, particularly at the initial treatment stage.
Downloads
References
Maurer M, Abuzakouk M, Berard F, Canonica W, Oude Elberink H, Gimenez-Arnau A, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy 2017; 72: 2005–2016. DOI: https://doi.org/10.1111/all.13209
Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022; 77: 734–766. DOI: https://doi.org/10.1111/all.15090
Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria: a GA(2)LEN task force report. Allergy 2011; 66: 317–330. DOI: https://doi.org/10.1111/j.1398-9995.2010.02496.x
Guillen-Aguinaga S, Jauregui Presa I, Aguinaga-Ontoso E, Guillen-Grima F, Ferrer M. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol 2016; 175: 1153–1165. DOI: https://doi.org/10.1111/bjd.14768
Weller K, Ohanyan T, Hawro T, Ellrich A, Sussman G, Koplowitz J, et al. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. Allergy 2018; 73: 2406–2408. DOI: https://doi.org/10.1111/all.13586
Olewicz-Gawlik A, Kowala-Piaskowska A. Self-reactive IgE and anti-IgE therapy in autoimmune diseases. Front Pharmacol 2023; 14: 1112917. DOI: https://doi.org/10.3389/fphar.2023.1112917
Fok JS, Kolkhir P, Church MK, Maurer M. Predictors of treatment response in chronic spontaneous urticaria. Allergy 2021; 76: 2965–2981. DOI: https://doi.org/10.1111/all.14757
Altrichter S, Fok JS, Jiao Q, Kolkhir P, Pyatilova P, Romero SM, et al. Total IgE as a marker for chronic spontaneous urticaria. Allergy Asthma Immunol Res 2021; 13: 206–218. DOI: https://doi.org/10.4168/aair.2021.13.2.206
Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbe A, Nelson L, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol 2019; 181: 761–769. DOI: https://doi.org/10.1111/bjd.17744
Stull D, McBride D, Tian H, Gimenez Arnau A, Maurer M, Marsland A, et al. Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria. Br J Dermatol 2017; 177: 1093–1101. DOI: https://doi.org/10.1111/bjd.15454
Trinh HK, Pham DL, Ban GY, Lee HY, Park HS, Ye YM. Altered systemic adipokines in patients with chronic urticaria. Int Arch Allergy Immunol 2016; 171: 102–110. DOI: https://doi.org/10.1159/000452626
Ulambayar B, Yang EM, Cha HY, Shin YS, Park HS, Ye YM. Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study. Clin Transl Allergy 2019; 9: 33. DOI: https://doi.org/10.1186/s13601-019-0275-6
Kessel A, Helou W, Bamberger E, Sabo E, Nusem D, Panassof J, et al. Elevated serum total IgE: a potential marker for severe chronic urticaria. Int Arch Allergy Immunol 2010; 153: 288–293. DOI: https://doi.org/10.1159/000314370
Cugno M, Genovese G, Ferrucci S, Casazza G, Asero R, Marzano AV. IgE and D-dimer baseline levels are higher in responders than nonresponders to omalizumab in chronic spontaneous urticaria. Br J Dermatol 2018; 179: 776–777. DOI: https://doi.org/10.1111/bjd.16593
Chuang KW, Hsu CY, Huang SW, Chang HC. Association between serum total IgE levels and clinical response to omalizumab for chronic spontaneous urticaria: a systematic review and meta-analysis. J Allergy Clin Immunol Pract 2023; 11: 2382–2389 e2383. DOI: https://doi.org/10.1016/j.jaip.2023.05.033
Santiago L, Ferreira B, Ramos L, Goncalo M. IgE levels are negatively correlated with clinical response to ciclosporin in chronic spontaneous urticaria. Br J Dermatol 2019; 180: 199–200. DOI: https://doi.org/10.1111/bjd.17005
Türk M, Ertas R, Sahiner UM, Kolkhir P, Sekerel BE, Soyer O, et al. In chronic spontaneous urticaria, complete response to antihistamine treatment is linked to low disease activity. Int Arch Allergy Immunol 2023; 184: 421–432. DOI: https://doi.org/10.1159/000528395
Kolkhir P, Munoz M, Asero R, Ferrer M, Kocaturk E, Metz M, et al. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol 2022; 149: 1819–1831. DOI: https://doi.org/10.1016/j.jaci.2022.04.010
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Yingyi Li, Rui Peng, Jingwen Xue, Yi Zhao
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
